You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 5, 2024

Investigational Drug Information for Navitoclax


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Navitoclax?

Navitoclax is an investigational drug.

There have been 30 clinical trials for Navitoclax. The most recent clinical trial was a Phase 2 trial, which was initiated on September 29th 2020.

The most common disease conditions in clinical trials are Leukemia, Lymphoid, Neoplasms, and Leukemia. The leading clinical trial sponsors are AbbVie, National Cancer Institute (NCI), and Genentech, Inc.

There are four hundred and sixteen US patents protecting this investigational drug and zero international patents.

Recent Clinical Trials for Navitoclax
TitleSponsorPhase
Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid LeukemiaMedical College of WisconsinPhase 1
HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesFight Kids CancerPhase 1/Phase 2
HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesIBFMPhase 1/Phase 2

See all Navitoclax clinical trials

Clinical Trial Summary for Navitoclax

Top disease conditions for Navitoclax
Top clinical trial sponsors for Navitoclax

See all Navitoclax clinical trials

US Patents for Navitoclax

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Navitoclax ⤷  Sign Up Pyrazol-3-ones that activate pro-apoptotic BAX Dana-Farber Cancer Institute, Inc. (Boston, MA) ⤷  Sign Up
Navitoclax ⤷  Sign Up Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders Dana-Farber Cancer Institute, Inc. (Boston, MA) ⤷  Sign Up
Navitoclax ⤷  Sign Up Methods for sensitizing a quiescent cancer stem cell to a BCR-ABL inhibitor The Regents of the University of California (Oakland, CA) ⤷  Sign Up
Navitoclax ⤷  Sign Up Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines Signal Pharmaceuticals, LLC (San Diego, CA) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Navitoclax

Drugname Country Document Number Estimated Expiration Related US Patent
Navitoclax Australia AU2012322660 2031-10-11 ⤷  Sign Up
Navitoclax Australia AU2017228527 2031-10-11 ⤷  Sign Up
Navitoclax Canada CA2851788 2031-10-11 ⤷  Sign Up
Navitoclax Canada CA3173988 2031-10-11 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.